6533b85dfe1ef96bd12be9ed
RESEARCH PRODUCT
Cemiplimab for locally advanced and metastatic cutaneous squamous-cell carcinomas: Real-life experience from the French CAREPI study group
Pierre-emmanuel StoebnerChristophe BedaneA. JannicMarc DumasMarie MoncourierSandrine MansardAnne-bénédicte Duval-modesteDavid SolubSophie DarrasSuzanne DevauxJulia SanchezNicolas MeyerLaurent MiseryValentine HeidelbergerRaoul TrillerIngrid Kupfer-bessaguetNathalie BenetonFlorence Brunet-possentiGaëlle QuéreuxGaëlle QuéreuxE. MaubecSophie DalacFrançois SkowronSafia AbedCaroline Gaudy-marquesteLaurent MortierMonica DinulescuF. HermsLucie PeuvrelMarouane BoubayaCandice HoberPierre GuilletMahtab SamimiYves ReguerreNicolas PoulalhonAnne Pham-ledardStéphanie CatalaEve-marie NeidhardtRomain LesbazeillesJean-philippe ArnaultBrigitte DrénoBrigitte DrénoOlivier CollardPhilippe CelerierJulie De QuatrebarbesYoussef TaziPierre CombeCaroline JacobzoneÉLodie ArchierF. AubinDominique SpaethClémence BerthinNora KramkimelFlorent GrangeCandice LesageLisa FredeauA. SchoefflerMarc PrachtBertille BonniaudLaure CesaireMaxime EtienneOlivier Lauchesubject
Cancer Researchmedicine.medical_specialtycutaneous squamous cell carcinomaLocally advancedBest Overall Response[SDV.CAN]Life Sciences [q-bio]/CancerGastroenterologyArticle030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineInternal medicineOverall survivalMedicineAdverse effectGroup performanceRC254-282Immune statusbusiness.industryNeoplasms. Tumors. Oncology. Including cancer and carcinogensMean agemedicine.diseasechronic dermatosisToxic epidermal necrolysis3. Good healthimmunocompromisedreal-life settingOncology030220 oncology & carcinogenesisPD-1–blocking antibodycemiplimabbusiness[SDV.MHEP.DERM]Life Sciences [q-bio]/Human health and pathology/Dermatologydescription
Although cemiplimab has been approved for locally advanced (la) and metastatic (m) cutaneous squamous-cell carcinomas (CSCCs), its real-life value has not yet been demonstrated. An early-access program enrolled patients with la/mCSCCs to receive cemiplimab. Endpoints were best overall response rate (BOR), progression-free survival (PFS), overall survival (OS), duration of response (DOR) and safety. The 245 patients (mean age 77 years, 73% male, 49% prior systemic treatment, 24% immunocompromised, 27% Eastern Cooperative Oncology Group performance status (PS) ≥ 2) had laCSCCs (35%) or mCSCCs (65%). For the 240 recipients of ≥1 infusion(s), the BOR was 50.4% (complete, 21%
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2021-07-01 |